Citigroup
C
American Express
AXP
Bank of America
BAC
MasterCard
MA
Visa
V
US Stock MarketDetailed Quotes
GLUE Monte Rosa Therapeutics
- 6.240
- +0.680+12.23%
Close Jan 15 16:00 ET
- 6.310
- +0.070+1.12%
Post 20:01 ET
383.37MMarket Cap-3.51P/E (TTM)
6.380High5.770Low1.39MVolume6.030Open5.560Pre Close8.37MTurnover3.76%Turnover RatioLossP/E (Static)61.44MShares12.40052wk High1.87P/B230.47MFloat Cap3.21052wk Low--Dividend TTM36.93MShs Float45.560Historical High--Div YieldTTM10.97%Amplitude2.440Historical Low6.025Avg Price1Lot Size
Monte Rosa Therapeutics News
Wells Fargo Downgrades Monte Rosa Therapeutics(GLUE.US) to Hold Rating, Cuts Target Price to $11
Wells Fargo Downgrades Monte Rosa Therapeutics to Equal-Weight, Lowers Price Target to $11
Monte Rosa Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV), Monte Rosa Therapeutics (GLUE) and CAMP4 Therapeutics Corporation (CAMP)
Piper Sandler Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Maintains Target Price $20
TD Cowen Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating
Wells Fargo Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Maintains Target Price $14
Analysts' Top Healthcare Picks: Insulet (PODD), Monte Rosa Therapeutics (GLUE)
Piper Sandler Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Raises Target Price to $20
J.P. Morgan Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Raises Target Price to $15
Wells Fargo Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Cuts Target Price to $14
TD Cowen Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating
Optimistic Outlook and Buy Rating on Monte Rosa Therapeutics Due to Promising Clinical Progress and Strategic Collaborations
Wells Fargo Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Maintains Target Price $17
Monte Rosa Therapeutics Price Target Maintained With a $11.00/Share by Wedbush
Analysts Offer Insights on Healthcare Companies: Molina Healthcare (MOH), Immunovant (IMVT) and Monte Rosa Therapeutics (GLUE)
Monte Rosa Therapeutics Analyst Ratings
Buy Rating Affirmed: Anticipated Catalysts and Undervaluation Set to Boost Monte Rosa Therapeutics
TD Cowen Keeps Their Buy Rating on Monte Rosa Therapeutics (GLUE)
Piper Sandler Reiterates Overweight on Monte Rosa Therapeutics, Maintains $16 Price Target
Trending US Stocks
Warren Buffett Portfolio Warren Buffett Portfolio
Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry. Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry.